Literature DB >> 15761534

Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors.

Emilia M Pinto1, Ana Elisa C Billerbeck, Maria Candida B F Villares, Sorahia Domenice, Berenice B Mendonça, Ana Claudia Latronico.   

Abstract

The incidence of adrenocortical tumors in children from the Southern region of Brazil is higher than in other parts of the world. This fact has been related to the identification of an inherited missense mutation of the p53 (R337H) at high frequency (78-97%) in Brazilian children with adrenocortical tumors. Given the high frequency of this germline mutation in the Brazilian population, it is very likely that the R337H mutation has arisen from a common origin. In this study, we analyzed two highly polymorphic intragenic markers (VNTRp53 and p53CA) in 22 patients (16 children and 6 adults) with adrenocortical tumors carrying the germline R337H mutation and 60 normal individuals using GeneScan Fragment Analysis software. We found six and sixteen different alleles for the VNTRp53 and p53CA polymorphic markers, respectively. Two distinct alleles, both with 122 bp, were found in 56.8% (VNTRp53) and 54.5% (p53CA) of the 44 alleles from patients with adrenocortical tumors associated with the R337H mutation. Differently, these same VNTRp53 and p53CA alleles were found in 18.3% and 14.2% of 120 alleles from normal individuals, respectively (p<0.01, Chi-square test). An identical haplotype for p53 locus was also identified in 95% of the apparently unrelated Brazilian patients with adrenocortical tumors carrying the R337H mutation. In conclusion, we demonstrated a strong evidence of co-segregation between two intragenic polymorphic p53 markers and the germline R337H mutation, indicating that this mutation has originated from a single common ancestral in the great majority of the Brazilian patients with adrenocortical tumors.

Entities:  

Mesh:

Year:  2005        PMID: 15761534     DOI: 10.1590/s0004-27302004000500009

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  50 in total

1.  Management and prognosis of adrenocortical tumors in children: can we find out an appropriate points-scoring system to predict prognosis?

Authors:  Wei Ru; Min Yang; Shan Xu; Minju Li; Daxing Tang
Journal:  Pediatr Surg Int       Date:  2017-03-04       Impact factor: 1.827

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 3.  Adrenocortical tumors and hyperplasias in childhood--etiology, genetics, clinical presentation and therapy.

Authors:  Jennifer A Sutter; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2006-09

4.  Childhood adrenocortical tumours: a review.

Authors:  Rosana Marques-Pereira; Luiz Delacerda; Hadriano M Lacerda; Edson Michalkiewicz; Fabiano Sandrini; Romolo Sandrini
Journal:  Hered Cancer Clin Pract       Date:  2006-05-15       Impact factor: 2.857

Review 5.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

6.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

Review 7.  The Inherited p53 Mutation in the Brazilian Population.

Authors:  Maria Isabel Achatz; Gerard P Zambetti
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

Review 8.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

9.  A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers.

Authors:  Jacquelyn Powers; Emilia M Pinto; Thibaut Barnoud; Jessica C Leung; Tetyana Martynyuk; Andrew V Kossenkov; Aaron H Philips; Heena Desai; Ryan Hausler; Gregory Kelly; Anh N Le; Marilyn M Li; Suzanne P MacFarland; Louise C Pyle; Kristin Zelley; Katherine L Nathanson; Susan M Domchek; Thomas P Slavin; Jeffrey N Weitzel; Jill E Stopfer; Judy E Garber; Vijai Joseph; Kenneth Offit; Jill S Dolinsky; Stephanie Gutierrez; Kelly McGoldrick; Fergus J Couch; Brooke Levin; Morris C Edelman; Carolyn Fein Levy; Sheri L Spunt; Richard W Kriwacki; Gerard P Zambetti; Raul C Ribeiro; Maureen E Murphy; Kara N Maxwell
Journal:  Cancer Res       Date:  2020-07-16       Impact factor: 12.701

10.  Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

Authors:  Gislaine Custódio; Guilherme A Parise; Nilton Kiesel Filho; Heloisa Komechen; Cesar C Sabbaga; Roberto Rosati; Leila Grisa; Ivy Z S Parise; Mara A D Pianovski; Carmem M C M Fiori; Jorge A Ledesma; José Renato S Barbosa; Francisco R O Figueiredo; Elis R Sade; Humberto Ibañez; Sohaila B I Arram; Sérvio T Stinghen; Luciano R Mengarelli; Mirna M O Figueiredo; Danilo C Carvalho; Sylvio G A Avilla; Thiago D Woiski; Lisiane C Poncio; Geneci F R Lima; Roberto Pontarolo; Enzo Lalli; Yinmei Zhou; Gerard P Zambetti; Raul C Ribeiro; Bonald C Figueiredo
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.